FiercePharma5d
ESMO: AstraZeneca's Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...
AIM Reports Positive Preliminary Data From Phase 1b/2 Study Of Ampligen, Imfinzi As Combination
AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and ...
ESMO 2024: Imfinzi to be practice changing in perioperative bladder cancer setting
The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.
Cure Today4d
Imfinzi Continuously Demonstrates Survival Benefit in Limited Stage SCLC
Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...
AstraZeneca and MSD hail progress in tackling hard-to-treat cancers
Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...
AZN : IMFINZI Regimen Reduces Death Risk By 25% In Late-Stage Muscle-Invasive Bladder Cancer Trial
AstraZeneca Plc (AZN.L, AZN) announced that the NIAGARA Phase III trial showed its IMFINZI (durvalumab) in combination with ...
Cure Today7d
Imfinzi After Primary Treatment Does Not Improve Disease-Free Survival in PD-L1-Positive NSCLC
Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.
The Pharma Letter4d
ESMO 2024: Imfinzi NIAGARA Phase III trial success in bladder cancer
Positive results from the NIAGARA Phase III trial showed that UK pharma major AstraZeneca’s (LSE: AZN) Imfinzi (durvalumab) ...